Clinical Trial 37589

Northridge, CA 91325


Study 37589 Flyer
Click image to enlarge

Protocol No.: 1VIT15043 version: 1.0, 12 January 2017

Inclusion Criteria:

A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency

Ferric Carboxymaltose (Injectafer®)

The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo, in the treatment of participants in heart failure with a reduced ejection fraction and with iron deficiency.

This is a double-blind, multicenter, prospective, randomized, placebo- controlled study to assess the effects of IV FCM compared to placebo on the 12-month rate of death, hospitalization for worsening heart failure, and the 6-month change in 6 minute walk test (6MWT) for patients in heart failure with iron deficiency. 

Qualified Participants May Receive:

All procedures, assessments, medications, laboratory draws at not cost. Participants receive compensation for time and travel.

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.